AVCNF and AVCN Related Headlines
Go Back- Avicanna Reports Q1 2026 Financial Statements
- Avicanna Announces Results of Annual General and Special Meeting
- Avicanna Announces Change in Board of Directors
- Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
- Annual General and Special Meeting of Shareholders to be held May 7, 2026
- Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics
- Avicanna appoints Ozgur Kilic to board, McVicar resigns
- Avicanna Announces Changes to its Board of Directors
- Avicanna Reports Full Year 2025 Audited Financial Statements
- Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
- Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
- Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
- Avicanna names Michael Kott to board as Paul Fornazzari resigns
- Avicanna Announces Changes to its Board of Directors
- Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
- Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform
- Avicanna Reports Q3 2025
- Avicanna Announces Change in CFO
- Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland
- Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States
- Avicanna Reports Q2 2025
- Avicanna Announces US Patent and Trademark Office Issuance of New Patent
- Avicanna Announces Results of Annual General Meeting
AVCNF and AVCN Related Press Releases
Go Back- Avicanna Reports Q1 2026 Financial Statements
- Avicanna Announces Results of Annual General and Special Meeting
- Avicanna Announces Change in Board of Directors
- Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
- Annual General and Special Meeting of Shareholders to be held May 7, 2026
- Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics
- Avicanna Announces Changes to its Board of Directors
- Avicanna Reports Full Year 2025 Audited Financial Statements
- Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
- Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
- Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
- Avicanna Announces Changes to its Board of Directors
- Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
- Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform
- Avicanna Reports Q3 2025
- Avicanna Announces Change in CFO
- Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland
- Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States
- Avicanna Reports Q2 2025
- Avicanna Announces US Patent and Trademark Office Issuance of New Patent
- Avicanna Announces Results of Annual General Meeting
